Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Diabetes Care 29:765-770, 2006
DOI: 10.2337/diacare.29.04.06.dc05-1894
© 2006 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheung, N. W.
Right arrow Articles by McLean, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheung, N. W.
Right arrow Articles by McLean, M.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical Care/Education/Nutrition
Original Article

The Hyperglycemia: Intensive Insulin Infusion In Infarction (HI-5) Study

A randomized controlled trial of insulin infusion therapy for myocardial infarction

N. Wah Cheung, PHD, Vincent W. Wong, PHD and Mark McLean, PHD

Centre for Diabetes & Endocrinology Research, Westmead Hospital and University of Sydney, Sydney, Australia

Address correspondence and reprint requests to N. Wah Cheung, Centre for Diabetes & Endocrinology Research, Westmead Hospital, Westmead, NSW 2145, Australia. Email: wah{at}westgate.wh.usyd.edu.au

OBJECTIVE—There is conflicting evidence regarding the benefit of intravenous insulin therapy on mortality following acute myocardial infarction (AMI). The goal of the current study was to determine whether improved glycemic control, achieved through an insulin/dextrose infusion with a variable rate of insulin, reduces mortality among hyperglycemic patients with AMI.

RESEARCH DESIGN AND METHODS—Subjects suffering AMI with either known diabetes or without diabetes but blood glucose level (BGL) ≥7.8 mmol/l were randomized to receive insulin/dextrose infusion therapy for at least 24 h to maintain a BGL <10 mmol/l or conventional therapy.

RESULTS—A total of 240 subjects were recruited. Insulin/dextrose infusion did not reduce mortality at the inpatient stage (4.8 vs. conventional 3.5%, P = 0.75), 3 months (7.1 vs 4.4%, P = 0.42), or 6 months (7.9 vs. 6.1%, P = 0.62). There was, however, a lower incidence of cardiac failure (12.7 vs. 22.8%, P = 0.04) and reinfarction within 3 months (2.4 vs. 6.1%, P = 0.05). When analyzed by mean BGL achieved during the first 24 h, mortality was lower among subjects with a mean BGL ≤8 mmol/l, compared with subjects with a mean BGL >8 mmol/l (2 vs. 11% at 6 months, P = 0.02).

CONCLUSIONS—We did not find a reduction in mortality among patients who received insulin/dextrose infusion therapy. However, it remains possible that tight glycemic control with insulin therapy following AMI improves outcomes.

Abbreviations: AMI, acute myocardial infarction • BGL, blood glucose level • CPK, creatinine phosphokinase • CREATE, Clinical Trial of Revirapine and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation • CTG, conventional therapy group • DIGAMI, Diabetes Insulin-Glucose infusion in Acute Myocardial Infarction • ECLA, Estudios Cardiologicos Latinoamerica • GIK, glucose-insulin-potassium • HI-5, Hyperglycemia: Intensive Insulin Infusion In Infarction • ITG, intensive insulin infusion therapy group • PTCA, percutaneous angioplasty


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
CirculationHome page
R. A. Kloner and R. W. Nesto
Glucose-Insulin-Potassium for Acute Myocardial Infarction: Continuing Controversy Over Cardioprotection
Circulation, May 13, 2008; 117(19): 2523 - 2533.
[Full Text] [PDF]


Home page
CirculationHome page
P. Deedwania, M. Kosiborod, E. Barrett, A. Ceriello, W. Isley, T. Mazzone, and P. Raskin
Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism
Circulation, March 25, 2008; 117(12): 1610 - 1619.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. W. Nesto and R. M. Lago
Glucose: A Biomarker in Acute Myocardial Infarction Ready for Prime Time?
Circulation, February 26, 2008; 117(8): 990 - 992.
[Full Text] [PDF]


Home page
CirculationHome page
M. Kosiborod, S. E. Inzucchi, H. M. Krumholz, L. Xiao, P. G. Jones, S. Fiske, F. A. Masoudi, S. P. Marso, and J. A. Spertus
Glucometrics in Patients Hospitalized With Acute Myocardial Infarction: Defining the Optimal Outcomes-Based Measure of Risk
Circulation, February 26, 2008; 117(8): 1018 - 1027.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes--2008
Diabetes Care, January 1, 2008; 31(Supplement_1): S12 - S54.
[Full Text] [PDF]


Home page
Diabetes CareHome page
A. Chaudhuri, M. Miller, R. Nesto, N. Rosenberg, and P. Dandona
Targeting Glucose in Acute Myocardial Infarction: Has glucose, insulin, and potassium infusion missed the target?
Diabetes Care, December 1, 2007; 30(12): 3026 - 3028.
[Full Text] [PDF]


Home page
HeartHome page
C Weston, L Walker, J Birkhead, and National Audit of Myocardial Infarction Project, N
Early impact of insulin treatment on mortality for hyperglycaemic patients without known diabetes who present with an acute coronary syndrome
Heart, December 1, 2007; 93(12): 1542 - 1546.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J., January 1, 2007; 28(1): 88 - 136.
[Full Text] [PDF]


Home page
NEJMHome page
S. E. Inzucchi
Management of Hyperglycemia in the Hospital Setting
N. Engl. J. Med., November 2, 2006; 355(18): 1903 - 1911.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Endocrinology & Metabolism News May 2006
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 17a - 17a.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2006 by the American Diabetes Association.